Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.